Billiontoone, Inc. (NASDAQ:BLLN) Short Interest Down 36.2% in May

Billiontoone, Inc. (NASDAQ:BLLN) was the target of a large decline in short interest in the month of May. As of May 15th, there was short interest totaling 1,465,466 shares, a decline of 36.2% from the April 30th total of 2,298,545 shares. Based on an average daily volume of 935,515 shares, the days-to-cover ratio is presently 1.6 days. Approximately 3.2% of the shares of the company are short sold.

Billiontoone Trading Up 4.4%

Shares of BLLN stock opened at $98.36 on Thursday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.58 and a current ratio of 10.92. The firm has a market capitalization of $4.52 billion and a PE ratio of 178.84. The stock has a fifty day moving average of $84.55 and a two-hundred day moving average of $88.01. Billiontoone has a 1 year low of $61.96 and a 1 year high of $138.70.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.33. The firm had revenue of $108.39 million during the quarter, compared to analyst estimates of $95.81 million. The company’s quarterly revenue was up 83.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.39) EPS. As a group, research analysts expect that Billiontoone will post 0.93 EPS for the current year.

Institutional Trading of Billiontoone

Institutional investors have recently modified their holdings of the company. Rossby Financial LCC acquired a new stake in shares of Billiontoone in the fourth quarter valued at $25,000. Wells Fargo & Company MN acquired a new stake in shares of Billiontoone in the fourth quarter valued at $76,000. Smartleaf Asset Management LLC acquired a new stake in shares of Billiontoone in the fourth quarter valued at $80,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Billiontoone in the fourth quarter valued at $82,000. Finally, Renaissance Capital LLC acquired a new stake in shares of Billiontoone in the fourth quarter valued at $201,000.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on BLLN. Wells Fargo & Company reduced their price objective on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a research report on Thursday, March 5th. Weiss Ratings upgraded Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, May 15th. JPMorgan Chase & Co. boosted their price objective on Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Guggenheim lifted their target price on Billiontoone from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. Finally, BTIG Research reduced their price target on Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $125.29.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.